US9820985 — Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Method of Use · Assigned to Medivation Technologies LLC · Expires 2029-07-27 · 3y remaining
What this patent protects
This patent protects pharmaceutical compositions that inhibit poly(ADP-ribose)polymerase activity and their use in treating diseases, disorders, and conditions.
USPTO Abstract
A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
U-2437 |
— | Talzenna |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.